Kidney News and Research

RSS

Study identifies a reductive uric acid degradation pathway in anaerobic bacteria

Uric acid builds up in the blood when the body cannot excrete it efficiently, leading to painful gout attacks, kidney stones, and other complications.

8 Sep 2025

Childhood blood pressure predicts cardiovascular mortality risk in adulthood

Blood pressure matters at all ages. Children with higher blood pressure at age 7 may be at an increased risk of dying of cardiovascular disease by their mid-50s, according to preliminary research presented at the American Heart Association's Hypertension Scientific Sessions 2025.

8 Sep 2025

WHO expands essential medicines lists with new cancer and diabetes treatments

Today, the World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.

5 Sep 2025

Study shows sharp increase in kidney disease deaths linked to high blood pressure

The death rate from hypertensive kidney disease (high blood pressure-related kidney disease) increased by 48% in the U.S. over the past 25 years, with continued differences across demographic groups, according to preliminary research presented at the American Heart Association's Hypertension Scientific Sessions 2025.

5 Sep 2025

First FDA-approved islet transplant at UI Health ends insulin dependence

Doctors at UI Health performed the first islet transplant with Lantidra, the only therapy approved by the U.S. Food and Drug Administration to treat brittle type 1 diabetes.

4 Sep 2025

Salt substitute use remains low among Americans with high blood pressure

Few people with high blood pressure were using salt substitutes, even though they are a simple and effective way to lower sodium intake and manage blood pressure, according to preliminary research presented at the American Heart Association's Hypertension Scientific Sessions 2025.

4 Sep 2025

Estrogen supports kidney regeneration and protects women from chronic disease

A new study in mice provides insights into why females in their reproductive years appear to be relatively protected from chronic kidney disease, a leading public health concern.

4 Sep 2025

Breast cancer cells hijack iron-handling macrophages to promote bone metastasis and anemia

Breast cancers frequently spread to the bone, establishing tumors that are largely impervious to treatment and are associated with poor patient prognoses.

4 Sep 2025

Changes at NIH give political appointees greater power to fund or block research

The Trump administration has given notice that political appointees, rather than scientists, will ultimately decide who gets grant money from the world’s largest biomedical research funder — the federal government's National Institutes of Health.

3 Sep 2025

How raspberry leaf tea reduces insulin surges from table sugar

Trial shows that raspberry leaf tea blunts sucrose-induced glucose and insulin surges, offering a natural strategy for moderating blood sugar without the side effects of pharmaceutical enzyme inhibitors.

2 Sep 2025

Heparanase 2 emerges as key protector of blood vessel integrity

An international research team led by MDI Biological Laboratory President Hermann Haller, M.D. and postdoctoral researcher Yannic Becker, Ph.D. has discovered that a little-known molecule, heparanase 2 (Hpa2), plays a critical role in maintaining blood vessels' integrity.

2 Sep 2025

Nanostructures boost CRISPR delivery for genetic medicine

With the power to rewrite the genetic code underlying countless diseases, CRISPR holds immense promise to revolutionize medicine. But until scientists can deliver its gene-editing machinery safely and efficiently into relevant cells and tissues, that promise will remain out of reach.

2 Sep 2025

Aptamer signs therapeutic development agreement with Invizius

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce that it has signed a new therapeutic development agreement with Invizius, a clinical-stage biotechnology company focused on second-generation complement system therapies for inflammatory, fibrotic, and autoimmune diseases.

From Aptamer Group 2 Sep 2025

Select groups of myocardial infarction patients benefit from Helicobacter pylori screening

Not all acute myocardial infarction patients should be offered routine screening for the stomach ulcer bacterium Helicobacter pylori.

1 Sep 2025

In-hospital start of dapagliflozin shows no significant short-term benefit in heart failure patients

In-hospital initiation of dapagliflozin did not significantly reduce the short-term risk of cardiovascular death or worsening heart failure (HF) in patients admitted for HF, although positive effects were seen when combining trial data, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Baxdrostat offers hope for millions with difficult-to-control high blood pressure

A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high, despite taking several existing medicines, according to the results of a Phase III clinical trial led by a UCL Professor.

1 Sep 2025

Adding aspirin raises cardiovascular events in high-risk CCS patients on anticoagulants

Adding aspirin increased the risk of cardiovascular events, death and major bleeding in high-risk patients with chronic coronary syndrome (CCS) who had prior stenting and were receiving long-term chronic oral anticoagulation (OAC), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Phase II trial finds zilebesiran lowers systolic blood pressure in patients with uncontrolled hypertension

Among individuals with cardiovascular disease or high cardiovascular risk and uncontrolled hypertension on multiple anti-hypertensive agents, a single subcutaneous dose of zilebesiran 300 mg led to a 5-mmHg reduction in systolic blood pressure at Month 3 compared with placebo, a difference that did not reach statistical significance.

1 Sep 2025

New trial shows benefit of digitoxin in patients with severe heart failure symptoms

Digitoxin reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and a reduced ejection fraction (HFrEF), according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Lubiprostone shows promise in slowing kidney disease progression

Chronic kidney disease (CKD) is a major health issue worldwide. Many patients end up requiring regular dialysis to avoid kidney failure and stay alive.

1 Sep 2025

Kidney News and Research

Study identifies a reductive uric acid degradation pathway in anaerobic bacteria

Childhood blood pressure predicts cardiovascular mortality risk in adulthood

WHO expands essential medicines lists with new cancer and diabetes treatments

Study shows sharp increase in kidney disease deaths linked to high blood pressure

First FDA-approved islet transplant at UI Health ends insulin dependence

Salt substitute use remains low among Americans with high blood pressure

Estrogen supports kidney regeneration and protects women from chronic disease

Breast cancer cells hijack iron-handling macrophages to promote bone metastasis and anemia

Changes at NIH give political appointees greater power to fund or block research

How raspberry leaf tea reduces insulin surges from table sugar

Heparanase 2 emerges as key protector of blood vessel integrity

Nanostructures boost CRISPR delivery for genetic medicine

Aptamer signs therapeutic development agreement with Invizius

Select groups of myocardial infarction patients benefit from Helicobacter pylori screening

In-hospital start of dapagliflozin shows no significant short-term benefit in heart failure patients

Baxdrostat offers hope for millions with difficult-to-control high blood pressure

Adding aspirin raises cardiovascular events in high-risk CCS patients on anticoagulants

Phase II trial finds zilebesiran lowers systolic blood pressure in patients with uncontrolled hypertension

New trial shows benefit of digitoxin in patients with severe heart failure symptoms

Lubiprostone shows promise in slowing kidney disease progression

Event guide: 8th CKD Summit 2026 eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News